Primary liver cancer, which is mainly composed of hepatocellular carcinoma (HCC), is the sixth most common type of cancer worldwide and the third most common cause of cancer mortality. The total number of mutations present in tumor specimens is called tumor mutation burden (TMB) anditisanemergingbiomarkerofimmunotherapy response. TMB can predict clinical responses to immunotherapy such as ICI (immune checkpoint inhibitor) treatments and higher TMB is related to better survival. TP53, a gene encoding a tumor suppressor protein that triggers apoptosis and cell cycle arrest, is one of the most prevalent mutations in 25% e30% of HCC patients. Research shows that TP53 mutations in HCC patients are associated with advanced tumor grade and poor prognosis. To identify the TP53 mutation-related genes which can predict HCC patients' prognosis and explore the immune cell infiltration, we constructed a risk model based on six TP53 mutation-related genes which can accurately predict patients' prognosis. Besides, six immune cells with a similar expression pattern were identified in The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases.